Among Asian Americans, lung cancer rates have been rising in the past several decades with no smoking history. Dr. Bryant […] ...
产品活性: Trastuzumab deruxtecan (T-DXd; DS-8201a) 是一种抗人表皮生长因子受体 2 (HER2) 抗体-活性分子偶联物 (ADC)。Trastuzumab deruxtecan 由人源化抗 HER2 ...
Reveal Genomics and the Istituto Europeo di Oncologia (IEO) have initiated an impact study of the genomic test, HER2DX, to ...
In August, the FDA approved Imfinzi (durvalumab) in combination with chemotherapy for adult patients with resectable ...
Elena Shagisultanova, MD, PhD, is working to uncover effective treatments for HER2-positive breast cancer patients by combining different drugs to counteract the cancer cells’ proliferation.
Merck & Co., Inc. (MRK) announced Tuesday that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation to ...
Dysregulated cell signaling underlies various diseases, emphasizing the importance of understanding these pathways for ...
The FDA has granted Breakthrough Therapy designation to sacituzumab tirumotecan for patients with advanced or metastatic ...
Both rare and aggressive, triple-negative breast cancer accounts for 10-15% of all breast cancers. Dr. Bhardwaj says, “TNBC ...
Merck (MRK) announced that the U.S. FDA has granted Breakthrough Therapy designation to sacituzumab tirumotecan for the treatment of patients with advanced or metastatic nonsquamous non-small cell ...
Arvinas, Inc. (Nasdaq: ARVN) today announced that three posters for vepdegestrant, including clinical data, will be presented ...